CD276 and ovarian carcinoma: Other investigational agents include chimeric antigen receptor (CAR) T cell therapy targeting B7-H3: 4SCAR-276 in solid tumors (NCT04432649), SCRI-CARB7H3 in pediatric CNS tumors (NCT04185038), B7-H3 chimeric antigen receptor T cells (CAR-T) treated alone (NCT04385173) or with temozolamide (NCT04077866) in glioblastoma, CAR.B7-H3 with other agents in epithelial ovarian cancer (NCT04670068), and second-generation 4-1BB B7H3-EGFRt-DHFR in non-primary CNS solid tumors (NCT04483778).